

12 March 2025

## RECEIPT OF CONVERTING NOTE FUNDS AND FINAL ASIC PAYMENT

Holista Colltech Limited (ASX: HCT) ("Holista" or "the Company") is pleased to announce that it has received the full funds from the Converting Notes totalling \$1.53m, as previously announced on 28 February 2025, with settlement completed on 11 March 2025. In accordance with the terms of the issuance, the Converting Notes have now been fully issued.

Additionally, the Company has successfully made the final payment of \$900,000 to the Australian Securities and Investments Commission (ASIC) on 11 March 2025, thereby fulfilling all outstanding obligations under the Federal Court order dated 17 May 2024.

Commenting on these developments, Holista Chair David Deloub stated:

"With this matter now behind us, the Company can continue to focus on driving our business forward."

These developments mark a significant milestone in Holista's financial strategy, reinforcing the Company's commitment to maintaining financial stability and regulatory compliance. The Board extends its appreciation to all stakeholders for their continued support.

This announcement has been authorised for release by the Board of Directors.

-- ENDS --

### ABOUT HOLISTA COLLTECH

Holista Colltech Ltd ("**Holista**") is a research-driven biotech company, a result of the merger of Holista Biotech Sdn Bhd and Colltech Australia Ltd. It is listed on the Australian Securities Exchange (**ASX:HCT**), headquartered in Perth and has extensive operations in multiple countries, including Malaysia and North America.

Holista's core business is to conduct research to find natural solutions so that people can live healthier lives. The Group holds proprietary solutions to help food manufacturers produce healthier alternatives – without use of chemicals – that do not compromise tastes and mouthfeel. Building on its partnership network and expertise, Holista has also developed advanced technologies related to collagen and nano-collagen.